Cannabinoid Treatment for Angelman Syndrome: A Groundbreaking Alliance Paves the Way
Cannabinoid treatment for Angelman Syndrome is witnessing a revolutionary advancement. The novel alliance between JettSet1 Enterprises and Biom Therapeutics marks a significant milestone in the journey towards an effective therapy.
Decoding Angelman Syndrome
Angelman Syndrome is a complex genetic disorder with a primary impact on the nervous system. Its characteristic features include delayed development, intellectual disability, severe speech impairment, and movement and balance difficulties. Most individuals with this condition also experience recurrent seizures and have a smaller head size, a condition known as microcephaly. The signs of this disorder start becoming noticeable between the age of 6 to 12 months.
People with Angelman Syndrome frequently exhibit a cheerful demeanor, characterized by constant smiling, laughter, and hand-flapping movements. Common accompanying conditions include hyperactivity and a short attention span. Sleep disturbances are common but tend to improve with age, even as the excitability decreases. However, intellectual disability, severe speech impairment, and seizures continue throughout the lifetime.
Biom Therapeutics: Spearheading Cannabidiol-based Drug Development
Biom Therapeutics, a preclinical-stage company, has gained recognition for its intensive research and development of Cannabidiol (CBD)-based drugs. Their concentrated efforts are targeted towards treating neurodevelopmental conditions, particularly Angelman Syndrome. The patent-pending, water-soluble CBD formulations developed by the company present a significant advancement in the field.
BIO017: A Ray of Hope for Angelman Syndrome
Biom Therapeutics’ lead drug candidate, BIO017, was granted the first and only orphan drug approval status by the FDA in March 2021 for treating Angelman Syndrome. This coveted status facilitates the development of therapies for severe and rare diseases, offering benefits such as seven years of market exclusivity and exemption from FDA application fees.
JettSet1 Enterprises: A Personal Mission and Vision
Flo Rida, a co-founder of JettSet1 and a globally renowned artist, brings a personal commitment to this alliance. As a parent of a child diagnosed with autism, his mission extends beyond business objectives. He aspires to bring attention to these ground-breaking scientific advancements, promoting awareness about neurodevelopmental disorders and potential treatments across the globe.
